Industry Trends_Heilongjiang Fulekang Pharmaceutical Co., Ltd.

2021-03

Li Li: Striving to Write a New Chapter in Drug Regulatory Work During the 14th Five-Year Plan Period

The quality and safety of pharmaceuticals are directly linked to the physical health and life safety of the people. They represent a serious political issue, a fundamental issue concerning people’s livelihoods, a major economic issue, and a rigorously technical one. The Party Central Committee and the State Council attach great importance to pharmaceutical regulatory work. General Secretary Xi Jinping has issued numerous important instructions and directives, emphasizing that the responsibility for pharmaceutical safety is as heavy as Mount Tai. We must earnestly strengthen the supervision of food and drug safety, adopting the most stringent standards, the strictest regulation, the harshest penalties, and the most serious accountability. We should accelerate the establishment of a scientific and comprehensive governance system for food and drug safety, uphold the principle of equal emphasis on production and regulation, and effectively safeguard the people’s rights to life and health.

2021-03-17

Li Li: Striving to Write a New Chapter in Drug Regulatory Work During the 14th Five-Year Plan Period

2021-03

Shaanxi Releases Drug Safety Assurance Plan for the 14th National Games

On March 16, a reporter learned from the Provincial Drug Administration that the agency recently issued the "Work Plan for Drug Safety Assurance for the 14th National Games, the 11th National Paralympic Games, and the 8th Special Olympics," which outlines the objectives, key measures, implementation steps, and requirements for drug safety assurance work. The "Work Plan" is divided into four phases: basic preparation, comprehensive testing and assurance, in-competition assurance, and summary and improvement. The "Work Plan" specifies that starting immediately, we have entered the comprehensive testing and assurance phase. During this period, drug regulatory authorities at the city and county levels are required to complete publicity and training on anti-doping laws, regulations, and related knowledge for relevant personnel at drug-related entities within their jurisdictions. Pharmaceutical retail enterprises must establish a catalog of drugs containing banned substances and set up dedicated counters for selling such drugs. They should also prominently display warning signs such as "Athletes should use drugs containing banned substances with caution" in conspicuous locations within their stores. Authorities should urge entities handling doping substances to promptly carry out self-inspections and rectifications as required. Drug regulatory agencies at all levels should fully leverage online information platforms and encourage retail pharmacies within their jurisdictions to use the WeChat mini-program "Shaanxi Drug Pass" as mandated, ensuring real-name registration of sales for relevant drugs. Furthermore, they should organize comprehensive inspections of the operation and use of doping substances within their jurisdictions, ensuring that any identified issues are thoroughly rectified and appropriately addressed. The "Work Plan" points out that from August 15 until the conclusion of the Games, we will enter the in-competition assurance phase. During this period, all retail pharmacies must strictly implement the real-name registration system for purchasing drugs containing banned substances. Drug regulatory authorities will intensify both visible and undercover inspections to ensure that the information registered by enterprises is authentic and complete. The Provincial Drug Administration will increase the frequency and intensity of both visible and undercover inspections, with a particular focus on monitoring the implementation of regulatory duties in districts (counties) hosting venues or sub-venues for the 14th National Games and the Paralympic Games. Drug regulatory authorities at the city and county levels should step up supervision and enforcement efforts in key areas including athlete accommodations, hotels, catering establishments, venues for various competitions, tourist attractions, airports, train stations, and entertainment venues. From the end of the Games until December 15, we will enter the summary and improvement phase. During this period, drug regulatory agencies at all levels should, based on actual conditions, comprehensively summarize the effective experiences and practices gained during the 14th National Games and the Paralympic Games, and establish and improve long-term mechanisms for drug safety assurance. (Reporter: Xu Ying) Source: Shaanxi Daily

2021-03-17

Shaanxi Releases Drug Safety Assurance Plan for the 14th National Games

2021-03

Medicines containing stimulants must be sold from dedicated counters. Our province has released a drug safety assurance plan for the 14th National Games and the Special Olympics for Persons with Disabilities.

According to a report from Xi'an News Network on the 16th, in order to ensure the successful and smooth hosting of the 14th National Games and the National Special Olympics for Persons with Disabilities in our province, the Provincial Drug Administration recently formulated the "Work Plan for Ensuring Pharmaceutical Safety during the 14th National Games, the 11th National Games for Persons with Disabilities, and the 8th Special Olympics." This plan clearly outlines the objectives, key tasks, specific measures, implementation steps, and requirements for pharmaceutical safety assurance. The plan is divided into four implementation phases: basic preparation, comprehensive testing and assurance, assurance during the competition period, and summary and improvement.

2021-03-17

Medicines containing stimulants must be sold from dedicated counters. Our province has released a drug safety assurance plan for the 14th National Games and the Special Olympics for Persons with Disabilities.

2021-01

In 2020, the total volume exceeded 2.38 billion. An Analysis of the Current Status, Challenges, and Trends in China’s Pharmaceutical E-commerce Industry

In 2020, the total financing amount exceeded 2.38 billion yuan. Analysis of the Current Status, Challenges, and Trends in China’s Pharmaceutical E-commerce Industry Under the impact of the pandemic, the greater health industry has attracted significant attention from capital investors. According to publicly disclosed data, in 2020, China’s internet-based greater health sector saw a total of 36 financing deals, with the overall funding amount surpassing 13.12 billion yuan, averaging 570 million yuan per deal. Among these, pharmaceutical e-commerce companies secured 10 financing deals totaling over 2.38 billion yuan. The financiers included Yi Yao Wang, Shangyao Cloud Health, Yi Bai Technology, Quanyuantang, Yiyi Medicine, Dingdang Kuaiyao, Yaobangshou, Yaodou.com, and Baideng Medical. Looking at the financing rounds, Series B led with 4 deals; Pre-Series and Series A each had 2 deals; while Angel and Series C each had 1 deal. In terms of financing cities, Beijing accounted for 3 deals; Changsha and Nanjing each had 2 deals; and Shanghai, Guangzhou, and Chengdu each had 1 deal. In fact, as early as 2019, the scale of China’s pharmaceutical e-commerce industry continued to expand, giving rise to many new retail models. An increasing number of pharmaceutical companies entered the mainstream B2B market, and the B2C market also experienced substantial growth driven by rising consumer health awareness and the establishment of online shopping habits. More and more pharmaceutical companies have also started engaging in O2O businesses. During the 2020 pandemic, the “medicine-to-doctor” and “doctor-plus-medicine” development models gained widespread recognition. 2019 China Pharmaceutical E-commerce Development: Total Sales Volume The total sales volume of directly reported pharmaceutical e-commerce enterprises in China (excluding A-certified companies) began to grow rapidly in 2015, and by 2019, it had surpassed 100 billion yuan. According to analysts at iiMedia Research, the sales volume of directly reported pharmaceutical e-commerce enterprises in China (excluding A-certified companies) will maintain an average annual compound growth rate of about 17%, and is expected to approach 140 billion yuan in 2021. 2019 China Pharmaceutical E-commerce Development: Market Share Proportion As China’s pharmaceutical e-commerce industry continues to develop, the share of pharmaceutical e-commerce sales in the overall pharmaceutical industry’s sales volume has been steadily increasing. In 2012, pharmaceutical e-commerce accounted for only 1.5% of the market share; by 2019, this proportion had exceeded 10%. Analysts at iiMedia Research believe that, with changing consumer behavior and the continued development of internet hospitals, as well as the growing integration between medicine-to-pharmacy and pharmacy-to-medicine models, pharmaceutical e-commerce will further demonstrate its vitality. Particularly under the influence of the 2020 pandemic, it is expected that the share of pharmaceutical e-commerce sales in China will maintain a growth rate of over 10% in both 2020 and 2021. 2020 China Pharmaceutical E-commerce Development: Impact of the Pandemic During this pandemic, the pharmaceutical e-commerce sales model—characterized by nationwide online coverage and rapid scaling—once again demonstrated the unique advantages and vitality of e-commerce. On one hand, pharmaceutical e-commerce met the demand for drug purchases without leaving home, catering to diverse needs across different regions nationwide. On the other hand, it greatly boosted product sales for pharmaceutical companies. However, the pandemic also exposed some issues with the B2B development model, with certain B2B e-commerce platforms showing limited effectiveness. 2020 China Pharmaceutical E-commerce Development: Daily Active Users During the 2020 Spring Festival, affected by the pandemic, the daily active users of pharmaceutical e-commerce significantly increased compared to normal periods, peaking at 1.4821 million users—a year-on-year growth rate of up to 10.11%, with an average growth rate of 5.44%. Analysts at iiMedia Research believe that this pandemic has, to some extent, stimulated the development of the pharmaceutical e-commerce industry. 2020 China Pharmaceutical E-commerce Development: Business Models 2020 China Pharmaceutical E-commerce Development Challenges: Negative Public Opinion According to iiMedia’s public opinion monitoring system, during the monitoring period, pharmaceutical e-commerce received relatively poor online reviews, with an online reputation score of only 20.3. Overall sentiment toward pharmaceutical e-commerce on the internet was predominantly neutral, accounting for 45.30%. In the word cloud of pharmaceutical e-commerce topics, several keywords related to policy measures impacting the development of the pharmaceutical industry appeared. 2020 China Pharmaceutical E-commerce Industry Development Trend: The “Medicine + Doctor” Model

2021-01-21

< 1 >

Heilongjiang Fulekang Pharmaceutical Co., Ltd.

Contact Address: No. 3 Yingbin Road, Niuji Industrial Park, Hanan Industrial New City, Harbin City, Heilongjiang Province

Fax: 0451-55893328

Domestic:0451-55893326-6023 13354500470

International:0451-55893326-6020

Personnel:0451-55893326-6002

Mobile phone:18845760808(WeChat same number)

Email:978590540@qq.com

Postal Code: 150221

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Website : 300.CN | SEO tags | Privacy Policy

Business license